Scholarlink

Background <p>Malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm arising from the mesothelial lining of the pleura.Despite advancements in systemic chemotherapy and targeted therapies, the prognosis for MPM remains poor, with a median survival of 8–14&#xa0;months. Standard treatment modalities include surgery in combination with radiotherapy and/or chemotherapy. Hyperthermic Intrathoracic Chemotherapy (HITOC) has emerged as a promising adjunct to surgery.</p> Case presentation <p>A 35-year-old Asian male was diagnosed with Stage II malignant pleural mesothelioma (T2N0M0). <Emphasis Type="BoldItalic">The patient underwent systemic chemotherapy consisting of six cycles of pemetrexed, carboplatin, and bevacizumab. The PET-CT demonstrated stabilization of the disease, with no evidence of metabolic activity or tumor growth, suggesting a positive response to chemotherapy</Emphasis>.Considering the localized nature of the disease and the absence of significant progression, the patient underwent cytoreductive surgery with Hyperthermic Intrathoracic Chemotherapy (HITOC) as the next step in treatment.</p> Conclusion <p>This case reports first successful application of HITOC for patient with MPM in Kazakhstan. It underscores the practical considerations, safety profile, and outcomes, contributing to the growing body of evidence supporting this approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First report of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Kalibekov Nurtas,
  • Digay Alexandr,
  • Zhaxybayev Bakhyt,
  • Mukazhanov Nurlan,
  • Shalekenov Sanzhar,
  • Burkitbayev Zhandos,
  • Jamilya Saparbay

摘要

Background

Malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm arising from the mesothelial lining of the pleura.Despite advancements in systemic chemotherapy and targeted therapies, the prognosis for MPM remains poor, with a median survival of 8–14 months. Standard treatment modalities include surgery in combination with radiotherapy and/or chemotherapy. Hyperthermic Intrathoracic Chemotherapy (HITOC) has emerged as a promising adjunct to surgery.

Case presentation

A 35-year-old Asian male was diagnosed with Stage II malignant pleural mesothelioma (T2N0M0). The patient underwent systemic chemotherapy consisting of six cycles of pemetrexed, carboplatin, and bevacizumab. The PET-CT demonstrated stabilization of the disease, with no evidence of metabolic activity or tumor growth, suggesting a positive response to chemotherapy.Considering the localized nature of the disease and the absence of significant progression, the patient underwent cytoreductive surgery with Hyperthermic Intrathoracic Chemotherapy (HITOC) as the next step in treatment.

Conclusion

This case reports first successful application of HITOC for patient with MPM in Kazakhstan. It underscores the practical considerations, safety profile, and outcomes, contributing to the growing body of evidence supporting this approach.